Search research articles
Contact Us
Filters
Showing results (821-830 of 856) with videos related to
Page
of 86
Sort By:
Genome Medicine
|
September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Emily Grist, Stefanie Friedrich, Christopher Brawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
Malcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
C T A Parker, H-C Huang, E Grist, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 13, 2009
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease
Robert L Martone, Hua Zhou, Kevin Atchison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Hannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Lancet (London, England)
|
May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
Chris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)
|
May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
Chris C Parker, Noel W Clarke, Adrian D Cook, et al.
Plos Medicine
|
June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Chris C Parker, Nicholas D James, Christopher D Brawley, et al.
Lancet (London, England)
|
October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher C Parker, Noel W Clarke, Adrian D Cook, et al.
The Lancet. Digital Health
|
June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
Charles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Page
of 86
Search research articles
Search
Showing results (821-830 of 856) with videos related to
Sort By:
Page
of 86
Genome Medicine
|
September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
Emily Grist, Stefanie Friedrich, Christopher Brawley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
Malcolm D Mason, Noel W Clarke, Nicholas D James, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2026
Multimodal Artificial Intelligence Prediction of Abiraterone Efficacy in Two STAMPEDE Phase 3 Trials of Non-Metastatic Very High-Risk Prostate Cancer
C T A Parker, H-C Huang, E Grist, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 13, 2009
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease
Robert L Martone, Hua Zhou, Kevin Atchison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2021
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
Hannah L Rush, Laura Murphy, Alicia K Morgans, et al.
Lancet (London, England)
|
May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
Chris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)
|
May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
Chris C Parker, Noel W Clarke, Adrian D Cook, et al.
Plos Medicine
|
June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
Chris C Parker, Nicholas D James, Christopher D Brawley, et al.
Lancet (London, England)
|
October 1, 2020
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Christopher C Parker, Noel W Clarke, Adrian D Cook, et al.
The Lancet. Digital Health
|
June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
Charles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Page
of 86